PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pharmaceutical Department, Usl Umbria 1, XIV Settembre Street, 06132 Perugia, Italy. Electronic address: antonio.vitiello2@uslumbria1.it.\', \'Clinical Pathology, Asur Marche, Viale Guido Da Montefeltro, Urbino, Italy. Electronic address: raffaele.laporta@sanita.marche.it.\', \'Pharmaceutical Department, Usl Umbria 1, A. Migliorati Street, 06132 Perugia, Italy. Electronic address: francesco.ferrara@uslumbria1.it.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0306-9877(21)00004-910.1016/j.mehy.2021.110486
?:doi
?:hasPublicationType
?:journal
  • Medical hypotheses
is ?:pmid of
?:pmid
?:pmid
  • 33460992
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.443
?:rankingScore_hIndex
  • 75
is ?:relation_isRelatedTo_publication of
?:title
  • Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33460992>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33460992>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all